Financial reports
10-K
2023 FY
Annual report
29 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Current reports
8-K
Regulation FD Disclosure
11 Apr 24
8-K
Regulation FD Disclosure
4 Apr 24
8-K
Regulation FD Disclosure
21 Feb 24
8-K
Other Events
6 Feb 24
8-K
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
30 Jan 24
8-K
NGC-Cap was better tolerated with positive preliminary efficacy results than FDA-approved capecitabine
25 Jan 24
8-K
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
19 Jan 24
8-K
Material Modifications to Rights of Security Holders
18 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU
19 Dec 23
Registration and prospectus
424B4
Prospectus supplement with pricing info
29 Jan 24
S-1/A
IPO registration (amended)
22 Jan 24
S-1
IPO registration
29 Dec 23
424B5
Prospectus supplement for primary offering
13 Feb 23
S-8
Registration of securities for employees
16 Aug 22
424B5
Prospectus supplement for primary offering
24 Mar 22
424B5
Prospectus supplement for primary offering
20 Aug 21
S-3
Shelf registration
30 Jun 21
S-8
Registration of securities for employees
30 Jun 21
424B3
Prospectus supplement
12 Apr 21
Proxies
DEFA14A
Additional proxy soliciting materials
5 Oct 23
DEF 14A
Definitive proxy
5 Oct 23
PRE 14A
Preliminary proxy
25 Sep 23
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
1 May 23
PRE 14A
Preliminary proxy
14 Apr 23
DEFA14A
Additional proxy soliciting materials
31 May 22
DEF 14A
Definitive proxy
31 May 22
DEFA14A
Additional proxy soliciting materials
20 Sep 21
DEF 14A
Definitive proxy
20 Sep 21
Other
EFFECT
Notice of effectiveness
29 Jan 24
CORRESP
Correspondence with SEC
22 Jan 24
CORRESP
Correspondence with SEC
22 Jan 24
UPLOAD
Letter from SEC
5 Jan 24
EFFECT
Notice of effectiveness
12 Jul 21
UPLOAD
Letter from SEC
6 Jul 21
CORRESP
Correspondence with SEC
6 Jul 21
EFFECT
Notice of effectiveness
13 Apr 21
CORRESP
Correspondence with SEC
7 Apr 21
UPLOAD
Letter from SEC
5 Apr 21